BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 25381575)

  • 1. ATF4: a Novel Potential Therapeutic Target for Alzheimer's Disease.
    Wei N; Zhu LQ; Liu D
    Mol Neurobiol; 2015 Dec; 52(3):1765-1770. PubMed ID: 25381575
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanism of Oxidative Stress and Synapse Dysfunction in the Pathogenesis of Alzheimer's Disease: Understanding the Therapeutics Strategies.
    Kamat PK; Kalani A; Rai S; Swarnkar S; Tota S; Nath C; Tyagi N
    Mol Neurobiol; 2016 Jan; 53(1):648-661. PubMed ID: 25511446
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Significance of tau in the development of Alzheimer's disease].
    Takashima A
    Brain Nerve; 2010 Jul; 62(7):701-8. PubMed ID: 20675874
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A NH2 tau fragment targets neuronal mitochondria at AD synapses: possible implications for neurodegeneration.
    Amadoro G; Corsetti V; Stringaro A; Colone M; D'Aguanno S; Meli G; Ciotti M; Sancesario G; Cattaneo A; Bussani R; Mercanti D; Calissano P
    J Alzheimers Dis; 2010; 21(2):445-70. PubMed ID: 20571215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The participation of insulin-like growth factor-binding protein 3 released by astrocytes in the pathology of Alzheimer's disease.
    Watanabe K; Uemura K; Asada M; Maesako M; Akiyama H; Shimohama S; Takahashi R; Kinoshita A
    Mol Brain; 2015 Dec; 8(1):82. PubMed ID: 26637371
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New Beginnings in Alzheimer's Disease: The Most Prevalent Tauopathy.
    Hernández F; Llorens-Martín M; Bolós M; Pérez M; Cuadros R; Pallas-Bazarra N; Zabala JC; Avila J
    J Alzheimers Dis; 2018; 64(s1):S529-S534. PubMed ID: 29562521
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The intersection of amyloid β and tau in glutamatergic synaptic dysfunction and collapse in Alzheimer's disease.
    Crimins JL; Pooler A; Polydoro M; Luebke JI; Spires-Jones TL
    Ageing Res Rev; 2013 Jun; 12(3):757-63. PubMed ID: 23528367
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Accumulated amyloid-beta peptide and hyperphosphorylated tau protein: relationship and links in Alzheimer's disease.
    Huang HC; Jiang ZF
    J Alzheimers Dis; 2009; 16(1):15-27. PubMed ID: 19158417
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tau function and dysfunction in neurons: its role in neurodegenerative disorders.
    Avila J; Lim F; Moreno F; Belmonte C; Cuello AC
    Mol Neurobiol; 2002 Jun; 25(3):213-31. PubMed ID: 12109872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amyloid-β and tau: the trigger and bullet in Alzheimer disease pathogenesis.
    Bloom GS
    JAMA Neurol; 2014 Apr; 71(4):505-8. PubMed ID: 24493463
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alpha1-antichymotrypsin, an inflammatory protein overexpressed in Alzheimer's disease brain, induces tau phosphorylation in neurons.
    Padmanabhan J; Levy M; Dickson DW; Potter H
    Brain; 2006 Nov; 129(Pt 11):3020-34. PubMed ID: 16987932
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interaction between NH(2)-tau fragment and Aβ in Alzheimer's disease mitochondria contributes to the synaptic deterioration.
    Amadoro G; Corsetti V; Atlante A; Florenzano F; Capsoni S; Bussani R; Mercanti D; Calissano P
    Neurobiol Aging; 2012 Apr; 33(4):833.e1-25. PubMed ID: 21958963
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neurofibrillary tangle formation by introducing wild-type human tau into APP transgenic mice.
    Umeda T; Maekawa S; Kimura T; Takashima A; Tomiyama T; Mori H
    Acta Neuropathol; 2014 May; 127(5):685-98. PubMed ID: 24531886
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isoaspartate formation and neurodegeneration in Alzheimer's disease.
    Shimizu T; Watanabe A; Ogawara M; Mori H; Shirasawa T
    Arch Biochem Biophys; 2000 Sep; 381(2):225-34. PubMed ID: 11032409
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plaque formation and the intraneuronal accumulation of β-amyloid in Alzheimer's disease.
    Takahashi RH; Nagao T; Gouras GK
    Pathol Int; 2017 Apr; 67(4):185-193. PubMed ID: 28261941
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An aluminum-based rat model for Alzheimer's disease exhibits oxidative damage, inhibition of PP2A activity, hyperphosphorylated tau, and granulovacuolar degeneration.
    Walton JR
    J Inorg Biochem; 2007 Sep; 101(9):1275-84. PubMed ID: 17662457
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Expression of apolipoprotein E in Alzheimer's disease and its significance].
    He SR; Liu DG; Wang S; Xia YJ
    Zhonghua Bing Li Xue Za Zhi; 2005 Sep; 34(9):556-60. PubMed ID: 16468304
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Roles of O-GlcNAcylation on amyloid-β precursor protein processing, tau phosphorylation, and hippocampal synapses dysfunction in Alzheimer's disease.
    Zheng BW; Yang L; Dai XL; Jiang ZF; Huang HC
    Neurol Res; 2016 Feb; 38(2):177-86. PubMed ID: 27078700
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Involvement of beta-amyloid in the etiology of Alzheimer's disease].
    Tomiyama T
    Brain Nerve; 2010 Jul; 62(7):691-9. PubMed ID: 20675873
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-tau based neuronal degeneration in Alzheimer's disease -- an immunocytochemical and quantitative study in the supragranular layers of the middle temporal neocortex.
    van de Nes JA; Nafe R; Schlote W
    Brain Res; 2008 Jun; 1213():152-65. PubMed ID: 18455153
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.